SILO PHARMA, INC. Deferred Compensation Arrangement with Individual, Allocated Share-based Compensation Expense
SILO PHARMA, INC. (SILO) reported Deferred Compensation Arrangement with Individual, Allocated Share-based Compensation Expense of $5.65 thousand for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense · last filed 2023-08-11
- SILO PHARMA, INC. deferred compensation arrangement with individual, allocated share-based compensation expense for the quarter ending 2023-06-30 was -$4.24K.
- SILO PHARMA, INC. deferred compensation arrangement with individual, allocated share-based compensation expense for the quarter ending 2023-03-31 was $9.89K, a 80.19% decline year-over-year.
- SILO PHARMA, INC. deferred compensation arrangement with individual, allocated share-based compensation expense for the quarter ending 2022-06-30 was -$28.25K.
- SILO PHARMA, INC. deferred compensation arrangement with individual, allocated share-based compensation expense for the quarter ending 2022-03-31 was $49.91K.
| Period end | Deferred Compensation Arrangement with Individual, Allocated Share-based Compensation Expense 3 month | Deferred Compensation Arrangement with Individual, Allocated Share-based Compensation Expense 6 month | Deferred Compensation Arrangement with Individual, Allocated Share-based Compensation Expense 6 month as first filed | Deferred Compensation Arrangement with Individual, Allocated Share-based Compensation Expense 12 month |
|---|---|---|---|---|
| 2023-06-30 | -$4.24K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $5.65K 10-Q · filed 2023-08-11 | ||
| 2023-03-31 | $9.89K 10-Q · filed 2023-05-12 | |||
| 2022-12-31 | $14.13K 10-Q · filed 2023-08-11 | |||
| 2022-06-30 | -$28.25K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-11-10 | $21.66K 10-Q · filed 2022-11-10 | $35.78K 10-Q · filed 2022-08-01 | |
| 2022-03-31 | $49.91K 10-Q · filed 2022-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |